Britain's National Health Service (NHS) has granted external workers, including contractors from Palantir Technologies Inc., broad access to patient-identifiable data as it develops a new health-data platform, according to a report from the Financial Times. The move has reignited a long-standing privacy debate surrounding one of the U.S. software giant's most sensitive public sector contracts.
The permissions extend to the National Data Integration Tenant (NDIT), a staging layer within the Federated Data Platform where patient records remain identifiable before pseudonymisation—the process of removing personal details. This arrangement has drawn sharp criticism from lawmakers and privacy advocates, who argue it poses significant risks to patient confidentiality.
Market Context and Financial Performance
Palantir's timing could hardly be more challenging. The company's stock has become a bellwether for investor appetite in AI-powered software across both public and private sectors. Just last week, Palantir reported an impressive 85% revenue growth, reaching $1.63 billion, and raised its 2026 sales forecast to between $7.65 billion and $7.66 billion. However, on Monday afternoon, shares slipped 1.1% to $136.27 on the Nasdaq, reflecting market jitters over the privacy controversy.
The NHS contract is particularly significant for Palantir, as its expansion relies heavily on public-sector contracts that are difficult to replace. Trust in the company's handling of sensitive data is now as critical as software quality. Palantir's core product allows clients to unify massive datasets and apply AI to them; in healthcare, this includes patient records, waitlists, scheduling, and a wide range of operational data that patients depend on but rarely interact with directly.
Privacy and Political Backlash
Several members of Parliament (MPs) and activists have warned that the decision could exacerbate public unease about Palantir's presence in UK public services. Labour MP Rachael Maskell described it as a “dangerous development,” while Liberal Democrat MP Martin Wrigley argued that the project seems to place data privacy below other priorities.
According to NHS England, Palantir acts as a “processor” under data law, handling information strictly on instructions from an NHS user, while a designated “controller” determines the reasons and methods for data use. NHS officials emphasize that access depends on user role and task, and that the data remains within the UK. Under its contract, Palantir is explicitly barred from commercialising NHS data or using it to train AI systems.
Contract Details and Operational Structure
Palantir leads the consortium that secured the contract in November 2023, valued at £330 million over seven years and potentially covering 240 NHS organisations. According to NHS England's contract explainer, only the first three years are locked in, with a review of the initial term scheduled for March 2027.
Palantir pitches the NHS platform as a solution for linking up siloed health-service data, promising faster access to vital information for clinicians, analysts, and operations teams. In a blog post last month, the company described the system's federated approach: each NHS organisation operates its own segment, retaining full control over local data.
Competitive Landscape and Valuation Concerns
Palantir's U.S. operations continue to drive results. First-quarter U.S. commercial revenue surged 133% to $595 million, and U.S. government revenue climbed 84% to $687 million. CEO Alex Karp described the U.S. business as “erupting” in his shareholder letter.
However, the company faces increasing competition. OpenAI announced Monday that it is launching a deployment company, investing over $4 billion to embed engineers directly within organizations to accelerate enterprise AI rollouts—a model that closely mirrors Palantir's signature hands-on approach.
Palantir's enviable run in the public sector and its lofty share price are now under pressure from two fronts: mounting privacy questions tied to its government work, and fresh doubts about its valuation on Wall Street. Jefferies analyst Brent Thill, in comments reported by TipRanks, argued that while Palantir's business remains solid, the stock demands what he called a “heroic durability assumption,” with risk versus reward still “unfavorable.”
The NHS dispute is ultimately about control, not contract loss. Palantir insists it will not use patient data outside the scope of customer instructions. Critics, however, argue that before any sensitive health records are processed in systems involving private AI contractors, the public deserves stricter boundaries.
